CRIS Current Research Information System

LENZI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.404
AS - Asia 6.200
EU - Europa 4.791
AF - Africa 378
SA - Sud America 318
Continente sconosciuto - Info sul continente non disponibili 287
OC - Oceania 23
Totale 20.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.305
VN - Vietnam 1.917
SG - Singapore 1.540
CN - Cina 1.504
GB - Regno Unito 1.144
IT - Italia 978
DE - Germania 588
SE - Svezia 573
HK - Hong Kong 355
FR - Francia 308
IN - India 287
UA - Ucraina 261
RU - Federazione Russa 239
BR - Brasile 214
IE - Irlanda 153
NL - Olanda 119
JP - Giappone 112
BD - Bangladesh 97
KR - Corea 95
ZA - Sudafrica 92
FI - Finlandia 91
EE - Estonia 86
CI - Costa d'Avorio 80
TG - Togo 67
AR - Argentina 57
CA - Canada 56
CH - Svizzera 54
SC - Seychelles 54
PH - Filippine 44
BG - Bulgaria 33
TR - Turchia 31
AT - Austria 30
JO - Giordania 30
TH - Thailandia 29
ID - Indonesia 27
PL - Polonia 27
NG - Nigeria 26
MX - Messico 23
PK - Pakistan 23
IQ - Iraq 21
BE - Belgio 19
ES - Italia 17
TW - Taiwan 17
AU - Australia 16
IR - Iran 13
EC - Ecuador 12
HR - Croazia 12
MA - Marocco 12
GR - Grecia 11
RO - Romania 10
SA - Arabia Saudita 10
TN - Tunisia 10
EG - Egitto 9
MY - Malesia 9
VE - Venezuela 9
LT - Lituania 8
UZ - Uzbekistan 8
DZ - Algeria 7
CL - Cile 6
KE - Kenya 6
NZ - Nuova Zelanda 6
UY - Uruguay 6
CZ - Repubblica Ceca 5
AO - Angola 4
CO - Colombia 4
JM - Giamaica 4
NP - Nepal 4
OM - Oman 4
PT - Portogallo 4
PY - Paraguay 4
SN - Senegal 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DK - Danimarca 3
LB - Libano 3
LV - Lettonia 3
MM - Myanmar 3
NI - Nicaragua 3
NO - Norvegia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AG - Antigua e Barbuda 2
BY - Bielorussia 2
CG - Congo 2
GH - Ghana 2
GT - Guatemala 2
IL - Israele 2
KZ - Kazakistan 2
PE - Perù 2
PS - Palestinian Territory 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AW - Aruba 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BZ - Belize 1
CR - Costa Rica 1
Totale 20.099
Salva come PNG Salva come JPEG
Città #
Singapore 1.061
Southend 977
Ashburn 765
Fairfield 745
Chandler 585
Dong Ket 451
San Jose 410
Houston 367
Woodbridge 360
Wilmington 342
Seattle 341
Ho Chi Minh City 335
Hong Kong 328
Hanoi 309
Santa Clara 305
Cambridge 266
Ann Arbor 263
Hefei 222
Princeton 213
Beijing 174
Jacksonville 164
Dublin 152
Bologna 147
Boardman 146
Lauterbourg 114
Nanjing 104
Los Angeles 99
Padova 97
Westminster 95
Tokyo 91
Milan 90
Council Bluffs 87
Helsinki 81
Abidjan 80
Dallas 79
Berlin 78
Seoul 76
Jinan 73
Lomé 67
Buffalo 66
New York 66
Da Nang 63
Frankfurt am Main 60
Haiphong 56
Shenyang 56
Rome 46
Saint Petersburg 41
Bern 39
San Diego 38
Changsha 37
São Paulo 34
Bremen 33
Turin 33
Mülheim 32
Sofia 32
Guangzhou 31
Amman 30
Redondo Beach 30
Des Moines 29
Hebei 29
Tianjin 29
Atlanta 28
Chicago 28
Nanchang 28
Phoenix 27
Abeokuta 26
London 25
Florence 24
Bengaluru 22
Biên Hòa 21
Medford 21
Zhengzhou 21
Falls Church 20
Vienna 20
Hải Dương 19
Jiaxing 19
Munich 19
Shanghai 19
Brussels 18
Can Tho 18
Haikou 18
Hangzhou 18
Orem 18
Verona 18
Falkenstein 17
San Francisco 17
Toronto 17
Warsaw 17
Yubileyny 17
Amsterdam 16
Mahé 15
Norwalk 15
Nuremberg 15
Taiyuan 15
Washington 15
Modena 14
Naples 14
Thái Nguyên 14
Dearborn 13
Montreal 13
Totale 12.388
Salva come PNG Salva come JPEG
Nome #
Easy recognition and high autoimmune hepatitis specificity of smooth muscle antibodies giving an actin microfilament immunofluorescent pattern on embryonal vascular smooth muscle cells 658
Development of autoimmune hepatitis after influenza vaccination; trigger or killer? 404
Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence 385
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 331
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 297
COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? 282
A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis 280
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 270
A deterministic solution of the Boltzmann transport equation for a one-dimensional electron gas in silicon nanowires 269
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 261
Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. 259
Clinical and serological profile of primary biliary cirrhosis in men. 250
Antinuclear antibodies in COVID 19 250
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 241
Anti-nuclear antibodies giving the “multiple nuclear dots” (MND) or the “rim-like/membranous” (RL/M) patterns: diagnostic accuracy for primary biliary cirrhosis. 238
Clinical features of type 1 autoimmune hepatitis in elderly Italian patients 236
Autoimmune liver disease and concomitant extrahepatic autoimmune disease 236
Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C 233
A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. 227
Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. 226
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 218
Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. 211
Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy 208
Antimitochondrial antibodies positive autoimmune hepatitis with acute onset 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 206
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 205
Autoantibodies in Autoimmune Hepatitis 201
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 201
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 200
Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry 194
Blood-Based Non-Invasive Tests of Hepatic Fibrosis in Autoimmune Hepatitis: Application among Selected Patients Leads to Higher Accuracy 194
CLINICAL FEATURES OF PRIMARY BILIARY CIRRHOSIS IN YOUNG AND ELDERLY PATIENTS. 194
Acute liver injury and anorexia nervosa: A case report 192
Semiclassical transport in silicon cylindrical nanowire FETs including surface roughness 192
HCV liver infection and liver steatosis:evidence for indirect mechanisms in genotype 3? 191
Diagnosis and therapy of autoimmune hepatitis. 191
Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype 188
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 188
Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. 186
Autoimmune liver disease 2007. 186
Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. 184
Autoimmune hepatitis in Italy: the Bologna experience. 180
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 179
Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study 179
Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. 178
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 177
The western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis 176
ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study 175
Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. 175
Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases 175
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment 174
Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. 172
Autoimmune hepatitis 171
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 171
Specific antinuclear reactivities in primary biliary cirrhosis 170
Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. 169
Standardization of Autoantibody Testing in Autoimmune Hepatitis 168
Immunoglobulin GM and KM allotypes and prevalence of anti-LKM1 autoantibodies in patients with hepatitis C virus infection. 165
INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. 162
Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia. 161
The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. 161
Diagnostic approach to autoimmune hepatitis 160
Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. 159
Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51 156
HCV and autoimmunity. 152
Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin 149
Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis 149
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. 148
Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. 148
Diagnosis of primary biliary cholangitis in a "teen" male patient 147
Primary biliary cholangitis-primary sclerosing cholangitis in an evolving overlap syndrome: A case report 145
Decompensated cirrhosis as presentation of LKM1/LC1 positive type 2 autoimmune hepatitis in adulthood. A rare clinical entity of difficult management 144
Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing 144
Coronavirus disease associated immune thrombocytopenia: Causation or correlation? 143
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group 142
Genetic distinction between autoimmune hepatitis in Italy and North America 139
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 138
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD 137
EASL Clinical Practice Guidelines: Autoimmune hepatitis 137
Serum Smooth Muscle Antibodies (SMA). 136
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 135
Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. 134
Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset 125
A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center 125
Expert clinical management of autoimmune hepatitis in the real world 124
Role of the HLA class II: HCV-related disorders. 124
Current topics in autoimmune hepatitis. 123
Preliminary classification criteria for the cryoglobulinaemic vasculitis 122
Non organ specific autoantibodies in children with chronic hepatitis C virus infection 121
LKM1-positive type 2 autoimmune hepatitis following allogenic haematopoietic stem-cell transplantation. 120
Liver HCV-antigens and steatosis in chronic hepatitis C: role of different genotypes 118
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis 116
Missed treatment in an Italian HBV infected patients cohort: HBV RER 116
Smooth muscle antibodies and type 1 autoimmune hepatitis 116
Susceptibility to thyroid disorders in hepatitis C 115
Vitamin D in autoimmune liver disease 115
The role of invariant NKT in autoimmune liver disease: Can Vitamin D Act as an Immunomodulator? 114
Genetic distinction between autoimmune hepatitis in Italy and North America: regional differences in the importance of HLA DR4 111
Totale 18.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.155 212 72 126 182 186 119 64 124 73 143 514 340
2022/20232.267 286 323 121 293 152 170 60 125 376 78 178 105
2023/2024650 52 87 35 56 46 103 26 53 31 26 73 62
2024/20252.572 136 398 259 212 427 145 129 76 41 167 96 486
2025/20266.023 510 510 505 408 645 313 626 194 1.274 489 229 320
2026/2027942 942 0 0 0 0 0 0 0 0 0 0 0
Totale 20.401